This HTML5 document contains 69 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01435/identifier/pubchem-compound/
n10http://linked.opendata.cz/resource/AHFS/
n6http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01435/identifier/pubchem-substance/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01435/identifier/kegg-drug/
n14http://linked.opendata.cz/resource/drugbank/mixture/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01435/identifier/drugbank/
n26http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n17http://linked.opendata.cz/resource/drugbank/drug/DB01435/identifier/chemspider/
n27http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01435/identifier/chebi/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/resource/drugbank/medicinal-product/
n5http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n7http://linked.opendata.cz/resource/drugbank/property/
n13http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01435/identifier/wikipedia/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/resource/drugbank/drug/DB01435/identifier/pharmgkb/
n24http://linked.opendata.cz/resource/atc/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01435
rdf:type
n3:Drug
n3:description
An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
n3:group
approved
n3:indication
Antipyrine is an analgesic often used to test effects of other drugs on liver enzymes..
owl:sameAs
n26:DB01435 n27:DB01435
dcterms:title
Antipyrine
adms:identifier
n16:D01776 n17:2121 n18:DB01435 n19:46505216 n20:PA448453 n21:2206 n22:Phenazone n23:31225
n3:mechanismOfAction
Antipyrine is thought to act primarily in the CNS, increasing the pain threshold by inhibiting both isoforms of cyclooxygenase, COX-1, COX-2, and COX-3 enzymes involved in prostaglandin (PG) synthesis.
n3:packager
n4:271B4A8B-363D-11E5-9242-09173F13E4C5
n3:synonym
Fenazon Phenazone Phenazon Analgesine Fenazona 1,2-Dihydro-1,5-dimethyl-2-phenyl-3H-pyrazol-3-one Antipyrine 2,3-Dimethyl-1-phenyl-5-pyrazolone
n9:hasAHFSCode
n10:92-02-00%2A
n3:mixture
n14:271B4A88-363D-11E5-9242-09173F13E4C5 n14:271B4A89-363D-11E5-9242-09173F13E4C5 n14:271B4A8A-363D-11E5-9242-09173F13E4C5
n3:synthesisReference
Andreas Burgard, "Xanthine-and phenazone-acesulfame-H complexes having improved taste, process for their preparation and their use." U.S. Patent US20030008865, issued January 09, 2003.
n5:hasConcept
n6:M0001499
foaf:page
n13:ant1656.shtml
n3:IUPAC-Name
n7:271B4A91-363D-11E5-9242-09173F13E4C5
n3:InChI
n7:271B4A97-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n7:271B4A96-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n7:271B4A93-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n7:271B4A94-363D-11E5-9242-09173F13E4C5
n3:SMILES
n7:271B4A95-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n7:271B4AA6-363D-11E5-9242-09173F13E4C5 n7:271B4A8F-363D-11E5-9242-09173F13E4C5
n3:logP
n7:271B4AA9-363D-11E5-9242-09173F13E4C5 n7:271B4A90-363D-11E5-9242-09173F13E4C5 n7:271B4A8D-363D-11E5-9242-09173F13E4C5
n3:logS
n7:271B4A8E-363D-11E5-9242-09173F13E4C5
n3:pKa
n7:271B4AAB-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n24:S02DA03 n24:N02BB01
n3:H-Bond-Acceptor-Count
n7:271B4A9D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n7:271B4A9E-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n7:271B4A98-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n7:271B4A99-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n7:271B4A9B-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n7:271B4A9A-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n7:271B4A9C-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:caco2-Permeability
n7:271B4AAA-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
60-80-0
n3:category
n3:containedIn
n8:271B4A8C-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n7:271B4AA2-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n7:271B4AA8-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n7:271B4AA4-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n7:271B4AA5-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n7:271B4AA7-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n7:271B4AA1-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n7:271B4AA0-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n7:271B4AA3-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n7:271B4A92-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n7:271B4A9F-363D-11E5-9242-09173F13E4C5